On top of the increased affinity of SARS-CoV-2 S1-RBD to ACE2 compared to SARS-CoV, new genetic variants with increased infectivity and virulence, likely arising under increased immunological pressure in patients suffering from COVID-19 or convalescent plasma therapy (Avanzato et al., 2020; Choi et al., 2020), have further complicated our efforts towards thwarting the pandemic. Here, ACE2 is linked to COVID-19.